JP5823093B2 - 低投与量のジクロフェナク及びβ−シクロデキストリンの配合物 - Google Patents
低投与量のジクロフェナク及びβ−シクロデキストリンの配合物 Download PDFInfo
- Publication number
- JP5823093B2 JP5823093B2 JP2009503166A JP2009503166A JP5823093B2 JP 5823093 B2 JP5823093 B2 JP 5823093B2 JP 2009503166 A JP2009503166 A JP 2009503166A JP 2009503166 A JP2009503166 A JP 2009503166A JP 5823093 B2 JP5823093 B2 JP 5823093B2
- Authority
- JP
- Japan
- Prior art keywords
- diclofenac
- pharmaceutical composition
- compound
- dose
- cyclodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229960001259 diclofenac Drugs 0.000 title claims description 69
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 title claims description 46
- 229920000858 Cyclodextrin Polymers 0.000 title claims description 25
- 235000011175 beta-cyclodextrine Nutrition 0.000 title claims description 19
- 239000001116 FEMA 4028 Substances 0.000 title claims description 18
- 229960004853 betadex Drugs 0.000 title claims description 18
- 239000000203 mixture Substances 0.000 title description 48
- 238000009472 formulation Methods 0.000 title description 46
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 title description 9
- -1 diclofenac compound Chemical class 0.000 claims description 46
- 239000008194 pharmaceutical composition Substances 0.000 claims description 38
- 230000036592 analgesia Effects 0.000 claims description 33
- 208000002193 Pain Diseases 0.000 claims description 25
- 230000036407 pain Effects 0.000 claims description 22
- 241000124008 Mammalia Species 0.000 claims description 14
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 14
- 229960001193 diclofenac sodium Drugs 0.000 claims description 10
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical group [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 claims description 10
- 239000003381 stabilizer Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 230000000007 visual effect Effects 0.000 claims description 4
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical group OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000003814 drug Substances 0.000 description 15
- 229940079593 drug Drugs 0.000 description 14
- 238000000034 method Methods 0.000 description 12
- 230000001988 toxicity Effects 0.000 description 11
- 231100000419 toxicity Toxicity 0.000 description 11
- 230000000202 analgesic effect Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000011282 treatment Methods 0.000 description 9
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 7
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 229960004752 ketorolac Drugs 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000007909 solid dosage form Substances 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 150000003973 alkyl amines Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940097362 cyclodextrins Drugs 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 241000272470 Circus Species 0.000 description 2
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229960004384 ketorolac tromethamine Drugs 0.000 description 2
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000006201 parenteral dosage form Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 239000004381 Choline salt Substances 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-UHFFFAOYSA-N alpha-D-glucopyranose Natural products OCC1OC(O)C(O)C(O)C1O WQZGKKKJIJFFOK-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019417 choline salt Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012972 dimethylethanolamine Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940038424 dyloject Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- ZEKANFGSDXODPD-UHFFFAOYSA-N glyphosate-isopropylammonium Chemical compound CC(C)N.OC(=O)CNCP(O)(O)=O ZEKANFGSDXODPD-UHFFFAOYSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- RZSCFTDHFNHMOR-UHFFFAOYSA-N n-(2,4-difluorophenyl)-2-[3-(trifluoromethyl)phenoxy]pyridine-3-carboxamide;1,1-dimethyl-3-(4-propan-2-ylphenyl)urea Chemical compound CC(C)C1=CC=C(NC(=O)N(C)C)C=C1.FC1=CC(F)=CC=C1NC(=O)C1=CC=CN=C1OC1=CC=CC(C(F)(F)F)=C1 RZSCFTDHFNHMOR-UHFFFAOYSA-N 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 210000004357 third molar Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78648606P | 2006-03-28 | 2006-03-28 | |
| US60/786,486 | 2006-03-28 | ||
| PCT/US2007/064678 WO2007112272A2 (en) | 2006-03-28 | 2007-03-22 | Formulations of low dose diclofenac and beta-cyclodextrin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013216668A Division JP6157305B2 (ja) | 2006-03-28 | 2013-10-17 | 低投与量のジクロフェナク及びβ−シクロデキストリンの配合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009531450A JP2009531450A (ja) | 2009-09-03 |
| JP2009531450A5 JP2009531450A5 (enExample) | 2011-09-29 |
| JP5823093B2 true JP5823093B2 (ja) | 2015-11-25 |
Family
ID=38541808
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009503166A Expired - Fee Related JP5823093B2 (ja) | 2006-03-28 | 2007-03-22 | 低投与量のジクロフェナク及びβ−シクロデキストリンの配合物 |
| JP2013216668A Expired - Fee Related JP6157305B2 (ja) | 2006-03-28 | 2013-10-17 | 低投与量のジクロフェナク及びβ−シクロデキストリンの配合物 |
| JP2015241131A Expired - Fee Related JP6265964B2 (ja) | 2006-03-28 | 2015-12-10 | 低投与量のジクロフェナク及びβ−シクロデキストリンの配合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013216668A Expired - Fee Related JP6157305B2 (ja) | 2006-03-28 | 2013-10-17 | 低投与量のジクロフェナク及びβ−シクロデキストリンの配合物 |
| JP2015241131A Expired - Fee Related JP6265964B2 (ja) | 2006-03-28 | 2015-12-10 | 低投与量のジクロフェナク及びβ−シクロデキストリンの配合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US8580954B2 (enExample) |
| EP (3) | EP2522343A1 (enExample) |
| JP (3) | JP5823093B2 (enExample) |
| KR (5) | KR20140038575A (enExample) |
| CN (2) | CN102846585A (enExample) |
| AU (1) | AU2007230716B2 (enExample) |
| BR (1) | BRPI0709409A2 (enExample) |
| CA (1) | CA2647348A1 (enExample) |
| IL (2) | IL194185A (enExample) |
| MX (1) | MX2008012495A (enExample) |
| WO (1) | WO2007112272A2 (enExample) |
| ZA (1) | ZA200808115B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2522343A1 (en) * | 2006-03-28 | 2012-11-14 | Javelin Pharmaceuticals, Inc. | Formulations of Low Dose Diclofenac and Beta-Cyclodextrin |
| MX2008012496A (es) * | 2006-03-28 | 2009-01-07 | Javelin Pharmaceuticals Inc | Formulaciones de farmacos anti-inflamatorios no esteroidales de baja dosis y beta-ciclodextrina. |
| EP2200649A4 (en) | 2007-10-19 | 2012-09-26 | Univ California | COMPOSITIONS AND METHODS FOR TREATING CNS INFUSION, PSYCHOSIS, DELIRE, PTSD OR PTSS |
| JP6194248B2 (ja) * | 2010-10-28 | 2017-09-06 | パシラ ファーマシューティカルズ インコーポレーテッド | 非ステロイド性抗炎症薬の徐放性処方物 |
| MY166036A (en) * | 2011-07-20 | 2018-05-21 | Hospira Inc | Methods of treating pain |
| US20140275261A1 (en) | 2013-03-15 | 2014-09-18 | Dr. Reddy's Laboratories, Inc. | Diclofenac parenteral compositions |
| CN107126418B (zh) * | 2016-02-25 | 2020-05-29 | 江苏思邈医药科技有限公司 | 供注射用双氯芬酸钠药物组合物及其制备方法 |
| CN109983013A (zh) | 2016-11-18 | 2019-07-05 | 帕西拉制药有限公司 | 美洛昔康锌复合物微粒多囊脂质体制剂及其制备方法 |
| US11110073B2 (en) | 2017-03-24 | 2021-09-07 | Cadila Healthcare Limited | Storage stable aqueous injectable solution comprising diclofenac |
| GB201720992D0 (en) * | 2017-12-15 | 2018-01-31 | Hooper Mark | A medical use |
| US20220280463A1 (en) | 2019-09-09 | 2022-09-08 | Ftf Pharma Private Limited | Pharmaceutical formulations comprising diclofenac |
| US11707443B2 (en) | 2019-09-26 | 2023-07-25 | Rk Pharma Inc. | Storage stable aqueous parenteral solutions comprising diclofenac |
| WO2023129171A1 (en) * | 2021-12-31 | 2023-07-06 | LIVIONEX, Inc. | Formulations of anti-inflammatory agents comprising msm with enhanced solubility in water |
Family Cites Families (137)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5984821U (ja) | 1982-11-30 | 1984-06-08 | 日新電機株式会社 | 積層コイル |
| JPS59188644A (ja) | 1983-04-09 | 1984-10-26 | Fuji Photo Film Co Ltd | 画像形成方法 |
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| DE3446873A1 (de) | 1984-12-21 | 1986-07-10 | Merckle Gmbh | Fluessige diclofenac-zubereitungen |
| GB8506792D0 (en) | 1985-03-15 | 1985-04-17 | Janssen Pharmaceutica Nv | Derivatives of y-cyclodextrin |
| US5785989A (en) | 1985-05-01 | 1998-07-28 | University Utah Research Foundation | Compositions and methods of manufacturing of oral dissolvable medicaments |
| US6407079B1 (en) | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| JPS62138437U (enExample) | 1986-02-26 | 1987-09-01 | ||
| YU43290B (en) | 1986-11-13 | 1989-06-30 | Lek Tovarna Farmacevtskih | Process for preparing inclusioned complex of ibuproxane with beta-cyclodextrine |
| JPH0616547Y2 (ja) | 1986-12-16 | 1994-05-02 | ヒゲタ醤油株式会社 | 諸味揚槽用濾布 |
| US5690954A (en) | 1987-05-22 | 1997-11-25 | Danbiosyst Uk Limited | Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material |
| US5017566A (en) | 1987-12-30 | 1991-05-21 | University Of Florida | Redox systems for brain-targeted drug delivery |
| US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| EP0335545B2 (en) | 1988-03-29 | 1998-09-23 | University Of Florida | Pharmaceutical formulations for parenteral use |
| JP2575460B2 (ja) * | 1988-05-12 | 1997-01-22 | 東京田辺製薬株式会社 | ダナゾール−シクロデキストリン包接化合物 |
| MY106598A (en) | 1988-08-31 | 1995-06-30 | Australian Commercial Res & Development Ltd | Compositions and methods for drug delivery and chromatography. |
| IT1227626B (it) | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
| BE1003009A5 (fr) * | 1989-02-09 | 1991-10-22 | Sandoz Sa | Nouvelles compositions pharmaceutiques a base de cyclosporines. |
| IT1241417B (it) | 1990-03-06 | 1994-01-14 | Vectorpharma Int | Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione |
| IT1243342B (it) | 1990-07-13 | 1994-06-10 | Farcon Ag | Composizioni farmaceutiche orali liquide ad attivita' antiinfiammatoria |
| JP3765579B2 (ja) | 1990-08-24 | 2006-04-12 | イーデーエーアー アーゲー | 作用物質投与用超微小滴状調剤 |
| EP1004318A3 (en) | 1991-06-21 | 2002-08-07 | Takeda Chemical Industries, Ltd. | Cyclodextrin composition |
| DE4207922A1 (de) | 1992-03-13 | 1993-09-23 | Pharmatech Gmbh | Wasserloesliche einschlussverbindungen und verfahren zu deren herstellung |
| IT1255522B (it) | 1992-09-24 | 1995-11-09 | Ubaldo Conte | Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita' |
| US5811547A (en) | 1992-10-14 | 1998-09-22 | Nippon Shinyaju Co., Ltd. | Method for inducing crystalline state transition in medicinal substance |
| US5389681A (en) | 1992-10-22 | 1995-02-14 | Ciba-Geigy Corporation | Parenteral solutions for diclofenac salts |
| IT1256386B (it) | 1992-11-13 | 1995-12-04 | Luigi Boltri | Composizioni farmaceutiche comprendenti un farmaco,una sostanza polimerica reticolata,un olio ed un agente tensioattivo |
| NZ267417A (en) | 1993-06-08 | 1997-02-24 | Ciba Geigy Ag | An inclusion compound of diclofenac and gamma-cyclodextrin and compressed dosage forms thereof |
| IT1264696B1 (it) | 1993-07-09 | 1996-10-04 | Applied Pharma Res | Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata |
| US5866162A (en) | 1993-08-10 | 1999-02-02 | Smithkline Beecham P.L.C. | Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base couple |
| GB9316580D0 (en) | 1993-08-10 | 1993-09-29 | Smithkline Beecham Plc | Pharmaceutical composition |
| GB9318880D0 (en) | 1993-09-11 | 1993-10-27 | Smithkline Beecham Plc | Pharmaceutical composition |
| IL111184A (en) | 1993-10-08 | 2000-08-13 | Farmarc Nederland B V Of Cito | Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin |
| US5540930A (en) | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
| EP0729748B1 (en) | 1993-11-18 | 2003-02-26 | Nippon Shinyaku Company, Limited | Process for producing stable medicinal composition |
| ZA949182B (en) | 1993-12-02 | 1995-07-26 | South African Druggists Ltd | Pharmaceutical composition |
| US5464633A (en) | 1994-05-24 | 1995-11-07 | Jagotec Ag | Pharmaceutical tablets releasing the active substance after a definite period of time |
| EP0760680A1 (en) | 1994-05-27 | 1997-03-12 | Farmarc Nederland Bv | Pharmaceutical composition |
| AU3609795A (en) | 1994-10-10 | 1996-05-02 | Novartis Ag | Ophthalmic and aural compositions containing diclofenac potassium |
| ZA959469B (en) | 1994-11-15 | 1996-05-15 | South African Druggists Ltd | Pharmaceutical composition |
| ATE215821T1 (de) | 1995-01-20 | 2002-04-15 | Wakamoto Pharma Co Ltd | Entzündungshemmende augentropfen |
| JP3934705B2 (ja) * | 1995-05-26 | 2007-06-20 | ノバルティス ファーマ株式会社 | サイクロデキストリン組成物 |
| US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
| US5821237A (en) | 1995-06-07 | 1998-10-13 | The Procter & Gamble Company | Compositions for visually improving skin |
| IT1276689B1 (it) | 1995-06-09 | 1997-11-03 | Applied Pharma Res | Forma farmaceutica solida ad uso orale |
| AU5774796A (en) | 1995-06-13 | 1997-01-09 | Dyer, Alison Margaret | Pharmaceutical compositions containing lornoxicam and cyclod extrin |
| TW434023B (en) | 1995-09-18 | 2001-05-16 | Novartis Ag | Preserved ophthalmic composition |
| HUP9600758A2 (en) | 1996-03-27 | 1998-03-02 | Cyclolab Ciklodextrin Kutato F | Diclofenac composition of diminished gastrointestinal irritation and enhanced biological resorption |
| FR2751875B1 (fr) | 1996-08-05 | 1998-12-24 | Scr Newpharm | Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation |
| EP0868915A1 (en) | 1997-04-02 | 1998-10-07 | Panacea Biotec Limited | An anti-spasmodic and antiinflammatory composition containing a NSAID, pentifenone and fenpiverinium |
| IT1291362B1 (it) | 1997-05-13 | 1999-01-07 | Vectorpharma Int | Composizioni farmaceutiche multicomponente bifasiche contenenti sostanze atte a modificare la partizione dei principi attivi |
| US6365180B1 (en) | 1998-01-20 | 2002-04-02 | Glenn A. Meyer | Oral liquid compositions |
| US6287594B1 (en) | 1998-01-20 | 2001-09-11 | Edward S. Wilson | Oral liquid compositions |
| US7772220B2 (en) | 2004-10-15 | 2010-08-10 | Seo Hong Yoo | Methods and compositions for reducing toxicity of a pharmaceutical compound |
| US6365182B1 (en) * | 1998-08-12 | 2002-04-02 | Cima Labs Inc. | Organoleptically pleasant in-mouth rapidly disintegrable potassium chloride tablet |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6313370B1 (en) | 1999-04-29 | 2001-11-06 | Morton Hyson | Medicated wrap |
| US7186260B2 (en) | 1999-04-29 | 2007-03-06 | Hyson Morton I | Medicated wrap |
| SV2002000055A (es) * | 1999-04-30 | 2002-07-03 | Lilly Icos Llc | Articulos de manufactura ref. n0. 29342/36212 sv |
| EP1185251A1 (en) | 1999-05-24 | 2002-03-13 | Purepac Pharmaceutical Co. | A pharmaceutical composition containing an active agent that is maintained in solid amorphous form and method of making the same |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| CO5261556A1 (es) | 1999-12-08 | 2003-03-31 | Pharmacia Corp | Composiciones inhibidoras de ciclooxigenasa-2 que tiene rapido acceso de efecto terapeutico |
| KR100416242B1 (ko) | 1999-12-22 | 2004-01-31 | 주식회사 삼양사 | 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법 |
| US20030113367A1 (en) | 2000-03-28 | 2003-06-19 | Penkler Lawrence John | Alprazolam inclusion complexes and pharmaceutical compositions thereof |
| AU2001259816A1 (en) | 2000-06-22 | 2002-01-02 | Advanced Medecine, Inc. | Polyhydroxy glycopeptide derivatives |
| PE20020146A1 (es) | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| JP2004508334A (ja) | 2000-09-08 | 2004-03-18 | フアルマシア・イタリア・エツセ・ピー・アー | 化学予防剤としてのエクセメスタン |
| EP1219304B1 (de) | 2000-12-28 | 2004-10-20 | Fresenius Kabi Austria GmbH | Stabile Infusionslösung von Diclofenac-Salzen, deren Herstellung und Verwendung |
| EP1219306A1 (en) | 2000-12-29 | 2002-07-03 | Nicox S.A. | Compositions comprising cyclodextrins and NO- releasing drugs |
| EP1377298B1 (en) | 2001-01-26 | 2006-08-30 | Pfizer Italia S.r.l. | Exemestane for treating hormono-dependent disorders |
| EP1386317A1 (de) * | 2001-03-28 | 2004-02-04 | Bayer Chemicals AG | Optischer datenträger enthaltend in der informationsschicht einen cyaninfarbstoff als lichtabsorbierende verbindung |
| US20080220441A1 (en) | 2001-05-16 | 2008-09-11 | Birnbaum Eva R | Advanced drug development and manufacturing |
| US20040137062A1 (en) | 2001-05-25 | 2004-07-15 | Sham Chopra | Chronotherapy tablet and methods related thereto |
| SE0102855D0 (sv) | 2001-08-27 | 2001-08-27 | Astrazeneca Ab | Method of treatment |
| FR2830017B1 (fr) | 2001-09-27 | 2005-11-04 | Centre Nat Rech Scient | Materiau compose d'au moins un polymere biodegradable et de cyclodextrines |
| WO2003033025A2 (en) | 2001-10-18 | 2003-04-24 | Decode Genetics Ehf | Cyclodextrin complexes |
| FR2834212B1 (fr) | 2001-12-27 | 2004-07-09 | Besins Int Belgique | Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques |
| WO2003063824A2 (en) | 2002-02-01 | 2003-08-07 | Shimoda Biotech (Pty) Ltd | Pharmaceutical composition |
| JP2005521690A (ja) | 2002-02-22 | 2005-07-21 | ファルマシア・コーポレーション | ゴム系を含む眼科用製剤 |
| US6869939B2 (en) | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| CN1232539C (zh) * | 2002-05-10 | 2005-12-21 | 刘云清 | 有机药物与倍他环糊精衍生物的配合物及其制备方法 |
| WO2003097011A1 (en) | 2002-05-17 | 2003-11-27 | Eisai Co., Ltd. | Compositions and methods using proton pump inhibitors |
| AU2003276957A1 (en) | 2002-06-13 | 2003-12-31 | Novartis Ag | Quaternised ammonium cyclodextrin compounds |
| FR2842736B1 (fr) | 2002-07-26 | 2005-07-22 | Flamel Tech Sa | Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s) |
| US7148211B2 (en) | 2002-09-18 | 2006-12-12 | Genzyme Corporation | Formulation for lipophilic agents |
| NZ540318A (en) | 2002-10-31 | 2007-09-28 | Umd Inc | Therapeutic compositions for drug delivery to and through covering epithelia |
| JP2006509788A (ja) | 2002-11-27 | 2006-03-23 | ファルマシア・コーポレーション | バルデコキシブの濃縮液体組成物 |
| EP1595936B1 (en) | 2003-01-27 | 2011-10-19 | Vitamin C60 Bioresearch Corporation | Composition for external use |
| KR20050111598A (ko) | 2003-02-19 | 2005-11-25 | 리나트 뉴로사이언스 코퍼레이션 | 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물 |
| WO2004081196A2 (en) | 2003-03-11 | 2004-09-23 | Qlt Usa Inc. | Formulations for cell- schedule dependent anticancer agents |
| US20050085446A1 (en) | 2003-04-14 | 2005-04-21 | Babu M.K. M. | Fluoroquinolone formulations and methods of making and using the same |
| US20070049552A1 (en) | 2003-04-14 | 2007-03-01 | Babu Manoj M | Fluoroquinolone formulations and methods of making and using the same |
| TW575271U (en) * | 2003-06-25 | 2004-02-01 | Wen-Chin Fan | Three-dimensional picture exhibiting device of image display |
| US20050095205A1 (en) | 2003-10-31 | 2005-05-05 | Ramesh Krishnamoorthy | Combination of loteprednol etabonate and tobramycin for topical ophthalmic use |
| US20050197303A1 (en) | 2003-10-31 | 2005-09-08 | Bausch & Lomb Incorporated | Combination of loteprednol etabonate and tobramycin for topical ophthalmic use |
| EP1681065A4 (en) | 2003-10-31 | 2011-12-28 | Wakamoto Pharma Co Ltd | WATER-BASED COMPOSITION SUBJECTED TO REVERSIBLE THERMOREGULATION |
| EP1734936B1 (en) | 2004-01-30 | 2014-09-10 | Rutgers, The State University | Amphiphilic star-like or scoprion-like macromolecules, various compositions and uses thereof |
| KR20050081092A (ko) | 2004-02-12 | 2005-08-18 | 한국과학기술연구원 | 생체적합성 친수성 고분자를 포함하는 콜로이드계 조성물,제형 및 이들의 제조 방법 |
| DE602004025151D1 (de) | 2004-03-10 | 2010-03-04 | Shimoda Biotech Pty Ltd | Stabile injizierbare Diclofenac- Zubereitungen |
| US20050203115A1 (en) | 2004-03-10 | 2005-09-15 | Sancilio Frederick D. | Narcotic-NSAID ion pairs |
| DE102004017351A1 (de) * | 2004-04-08 | 2005-10-27 | Kalle Gmbh | Schlauchförmige Nahrungsmittelhülle mit übertragbarer Innenschicht |
| US8128954B2 (en) | 2004-06-07 | 2012-03-06 | California Institute Of Technology | Biodegradable drug-polymer delivery system |
| JP2008502609A (ja) | 2004-06-17 | 2008-01-31 | オステオロジックス エイ／エス | リウマチおよび関節性疾患の治療改善方法 |
| ITMI20041245A1 (it) | 2004-06-22 | 2004-09-22 | Ibsa Inst Biochimique Sa | Composizioni farmaceutiche iniettabnili comprendenti diclofenac sodico e b-ciclodestrina |
| TWI279226B (en) | 2004-07-20 | 2007-04-21 | Schoeller Textil Ag | Dressings which can be applied several times to textile fibres and textile fabrics |
| GB2417900A (en) | 2004-09-11 | 2006-03-15 | Medway Science Technologies Lt | Composition for oral drug delivery |
| CA2582374A1 (en) | 2004-10-04 | 2006-04-20 | Qlt Usa, Inc. | Ocular delivery of polymeric delivery formulations |
| DE602005027727D1 (de) | 2004-10-15 | 2011-06-09 | Seo Hong Yoo | Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin |
| US20080233053A1 (en) | 2005-02-07 | 2008-09-25 | Pharmalight Inc. | Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients |
| US7140694B2 (en) * | 2005-03-29 | 2006-11-28 | Steven Mason | Wheel spoke adjuster guard |
| KR101255650B1 (ko) * | 2005-05-04 | 2013-04-16 | 프로노바 바이오파마 너지 에이에스 | 새로운 ｄｈａ 유도체 및 약제로서의 용도 |
| CN103145837A (zh) | 2005-06-30 | 2013-06-12 | Abbvie公司 | Il-12/p40结合蛋白 |
| EP1898922A4 (en) | 2005-07-04 | 2012-03-14 | Ramu Krishnan | MEDICINE OR IMPROVED PHARMACEUTICAL COMPOUNDS AND PREPARATION THEREOF |
| EP1906937B1 (en) | 2005-07-22 | 2016-10-19 | Rubicon Research Pvt Ltd. | Novel dispersible tablet composition |
| WO2007061739A2 (en) | 2005-11-21 | 2007-05-31 | Schering-Plough Ltd. | Pharmaceutical compositions comprising buprenorphine |
| EP3263117A1 (en) | 2005-11-28 | 2018-01-03 | Imaginot Pty Ltd. | Oral therapeutic compound delivery system |
| JP5196130B2 (ja) | 2005-12-27 | 2013-05-15 | ライオン株式会社 | ソフトコンタクトレンズ用組成物及び吸着抑制方法 |
| EP1998788A4 (en) | 2006-03-01 | 2011-08-03 | Ruey J Yu | COMPOSITIONS AND METHODS FOR THE TOPIC TREATMENT OF DERMATOLOGICAL DISORDERS RESPONSIBLE FOR TAR |
| US9192644B2 (en) | 2006-03-06 | 2015-11-24 | The Regents Of The University Of California | Bioavailable curcuminoid formulations for treating Alzheimer's disease and other age-related disorders |
| US7767217B2 (en) | 2006-03-14 | 2010-08-03 | Foresight Biotherapeutics | Ophthalmic compositions comprising povidone-iodine |
| EP2522343A1 (en) | 2006-03-28 | 2012-11-14 | Javelin Pharmaceuticals, Inc. | Formulations of Low Dose Diclofenac and Beta-Cyclodextrin |
| MX2008012496A (es) | 2006-03-28 | 2009-01-07 | Javelin Pharmaceuticals Inc | Formulaciones de farmacos anti-inflamatorios no esteroidales de baja dosis y beta-ciclodextrina. |
| WO2008006216A1 (en) | 2006-07-14 | 2008-01-17 | Mistral Pharma, Inc. | Anti-inflammatory and cytoprotectant chronotherapy |
| HUE052220T2 (hu) | 2006-09-08 | 2021-04-28 | Abbvie Bahamas Ltd | Interleukin-13 kötõfehérjék |
| HUE038022T4 (hu) | 2006-10-02 | 2023-02-28 | Spepharm Ag | Nem mukoadhezív filmdózisformák |
| EP2084519B1 (en) | 2006-10-10 | 2012-08-01 | Los Alamos National Security, LLC | X-ray fluorescence analysis method |
| FI20065800A0 (fi) | 2006-12-13 | 2006-12-13 | Glykos Finland Oy | Polyvalentit biokonjugaatit |
| JP2010513551A (ja) | 2006-12-18 | 2010-04-30 | アラーガン インコーポレイテッド | 胃腸疾患の治療方法および組成物 |
| US20100166870A1 (en) | 2006-12-21 | 2010-07-01 | The University Of Western Australia | Method for Coating Nanoparticles |
| WO2008115572A1 (en) | 2007-03-21 | 2008-09-25 | Theraquest Biosciences, Inc. | Methods and compositions of nsaids |
| EP1974751A1 (en) | 2007-03-26 | 2008-10-01 | The Jordanian Pharmaceutical Manufacturing Co. | Formulations for non-steroidal anti-inflammatory drugs |
| CN101686681B (zh) | 2007-04-27 | 2015-04-01 | 锡德克斯药物公司 | 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法 |
| WO2008133982A2 (en) | 2007-04-27 | 2008-11-06 | Lectec Corporation | Adhesive patch with aversive agent |
| US7662858B2 (en) | 2008-05-23 | 2010-02-16 | Aaipharma, Inc. | Method of treating post-surgical acute pain |
| MY166036A (en) * | 2011-07-20 | 2018-05-21 | Hospira Inc | Methods of treating pain |
-
2007
- 2007-03-22 EP EP20120164654 patent/EP2522343A1/en not_active Withdrawn
- 2007-03-22 CN CN201210342041XA patent/CN102846585A/zh active Pending
- 2007-03-22 CA CA 2647348 patent/CA2647348A1/en not_active Abandoned
- 2007-03-22 CN CNA2007800115094A patent/CN101410123A/zh active Pending
- 2007-03-22 AU AU2007230716A patent/AU2007230716B2/en not_active Ceased
- 2007-03-22 KR KR1020147007290A patent/KR20140038575A/ko not_active Ceased
- 2007-03-22 KR KR1020177031515A patent/KR20170123724A/ko not_active Ceased
- 2007-03-22 KR KR1020157010213A patent/KR20150050595A/ko not_active Ceased
- 2007-03-22 KR KR1020087024795A patent/KR20080112285A/ko not_active Ceased
- 2007-03-22 JP JP2009503166A patent/JP5823093B2/ja not_active Expired - Fee Related
- 2007-03-22 WO PCT/US2007/064678 patent/WO2007112272A2/en not_active Ceased
- 2007-03-22 KR KR1020167006852A patent/KR20160033796A/ko not_active Ceased
- 2007-03-22 EP EP07759156A patent/EP2004203A4/en not_active Ceased
- 2007-03-22 US US11/689,931 patent/US8580954B2/en not_active Expired - Fee Related
- 2007-03-22 BR BRPI0709409-4A patent/BRPI0709409A2/pt not_active Application Discontinuation
- 2007-03-22 EP EP20120164658 patent/EP2522344A1/en not_active Withdrawn
- 2007-03-22 MX MX2008012495A patent/MX2008012495A/es active IP Right Grant
-
2008
- 2008-09-17 IL IL194185A patent/IL194185A/en not_active IP Right Cessation
- 2008-09-22 ZA ZA2008/08115A patent/ZA200808115B/en unknown
-
2011
- 2011-05-12 US US13/106,697 patent/US8946292B2/en active Active
-
2012
- 2012-10-14 IL IL222432A patent/IL222432A/en not_active IP Right Cessation
-
2013
- 2013-10-10 US US14/051,021 patent/US20140107209A1/en not_active Abandoned
- 2013-10-17 JP JP2013216668A patent/JP6157305B2/ja not_active Expired - Fee Related
-
2014
- 2014-12-19 US US14/576,404 patent/US20150105467A1/en not_active Abandoned
-
2015
- 2015-12-10 JP JP2015241131A patent/JP6265964B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6265964B2 (ja) | 低投与量のジクロフェナク及びβ−シクロデキストリンの配合物 | |
| JP2009531451A (ja) | 低投与量の非ステロイド系抗炎症薬及びβ−シクロデキストリンの配合物 | |
| JP6095707B2 (ja) | 薬学的組成物 | |
| JP2007528384A (ja) | 安定な注射可能なジクロフェナク組成物 | |
| WO2020089286A1 (en) | Cyclodextrin-based formulation of a bcl-2 inhibitor | |
| JP2021514393A (ja) | 複数回使用のトラセミド組成物 | |
| JP2006509788A (ja) | バルデコキシブの濃縮液体組成物 | |
| AU2012209035B2 (en) | Formulations of low dose diclofenac and beta-cyclodextrin | |
| JP2017538762A (ja) | パラセタモールの注射用製剤 | |
| HK1180247A (en) | Formulations of low dose diclofenac and beta-cyclodextrin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100323 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100323 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110815 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120903 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121203 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121210 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130301 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130617 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131017 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20131129 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140106 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20140221 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150422 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150803 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151007 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5823093 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |